Kezar Life Sciences to Present at BIO CEO & Investor Digital Conference
Kezar Life Sciences (Nasdaq: KZR) announced that CEO John Fowler will present at the BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will be available on demand starting February 16 on their website. Additionally, Chief Scientific Officer Chris Kirk, Ph.D., will join a panel on drugging undruggable cancer targets. Kezar specializes in developing innovative treatments for immune-mediated and oncologic disorders, with lead candidate KZR-616 in Phase 2 trials for lupus nephritis, dermatomyositis, and polymyositis.
- None.
- None.
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporate overview at the BIO CEO & Investor Digital Conference, being held from February 16 – 18, 2021. Kezar’s Chief Scientific Officer, Chris Kirk, Ph.D., will participate in a panel discussion, “Progress in Drugging the Undruggable Cancer Targets” at the conference.
The presentation will be available on demand on Tuesday, February 16, 2021 and may be accessed at the “Events & Presentations” section of the Company’s website at http://investors.kezarlifesciences.com/events. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.
About Kezar Life Sciences
Based in South San Francisco, Kezar Life Sciences is a clinical-stage biopharmaceutical company bringing novel treatments to patients with rare autoimmune diseases and cancer. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead development candidate, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis. Additionally, KZR-261, the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway, is undergoing IND-enabling activities. For more information, visit www.kezarlifesciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005622/en/
FAQ
When will Kezar Life Sciences present at the BIO CEO & Investor Digital Conference?
Who is participating in the panel discussion at the conference?
How can I access the presentation from Kezar Life Sciences?
What is KZR-616 and its current clinical status?
What other candidates is Kezar Life Sciences developing?
